These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

625 related articles for article (PubMed ID: 8545225)

  • 1. Benefit of primary prophylaxis before 18 months of age in reducing the incidence of Pneumocystis carinii pneumonia and early death in a cohort of 112 human immunodeficiency virus-infected infants. New York City Perinatal HIV Transmission Collaborative Study Group.
    Thea DM; Lambert G; Weedon J; Matheson PB; Abrams EJ; Bamji M; Straus WL; Thomas PA; Krasinski K; Heagarty M
    Pediatrics; 1996 Jan; 97(1):59-64. PubMed ID: 8545225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pneumocystis prophylaxis and survival in patients with advanced human immunodeficiency virus infection treated with zidovudine. The Zidovudine Epidemiology Group.
    Chaisson RE; Keruly J; Richman DD; Moore RD
    Arch Intern Med; 1992 Oct; 152(10):2009-13. PubMed ID: 1417373
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prophylaxis against Pneumocystis carinii pneumonia among children with perinatally acquired human immunodeficiency virus infection in the United States. Pneumocystis carinii Pneumonia Prophylaxis Evaluation Working Group.
    Simonds RJ; Lindegren ML; Thomas P; Hanson D; Caldwell B; Scott G; Rogers M
    N Engl J Med; 1995 Mar; 332(12):786-90. PubMed ID: 7862183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of pregnancy on maternal AIDS.
    Kumar RM; Uduman SA; Khurrana AK
    J Reprod Med; 1997 Jul; 42(7):429-34. PubMed ID: 9252934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. The Dutch AIDS Treatment Group.
    Schneider MM; Hoepelman AI; Eeftinck Schattenkerk JK; Nielsen TL; van der Graaf Y; Frissen JP; van der Ende IM; Kolsters AF; Borleffs JC
    N Engl J Med; 1992 Dec; 327(26):1836-41. PubMed ID: 1360145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 1995 revised guidelines for prophylaxis against Pneumocystis carinii pneumonia for children infected with or perinatally exposed to human immunodeficiency virus. National Pediatric and Family HIV Resource Center and National Center for Infectious Diseases, Centers for Disease Control and Prevention.
    MMWR Recomm Rep; 1995 Apr; 44(RR-4):1-11. PubMed ID: 7565543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pneumocystis carinii pneumonia in human immunodeficiency virus-infected infants and children.
    Goodwin SD
    Pharmacotherapy; 1993; 13(6):640-6. PubMed ID: 8302691
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD4 T cell count as predictor of Pneumocystis carinii pneumonia in children born to mothers infected with HIV. European Collaborative Study Group.
    BMJ; 1994 Feb; 308(6926):437-40. PubMed ID: 7907246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized trial of the discontinuation of primary and secondary prophylaxis against Pneumocystis carinii pneumonia after highly active antiretroviral therapy in patients with HIV infection. Grupo de Estudio del SIDA 04/98.
    Lopez Bernaldo de Quiros JC; Miro JM; Peña JM; Podzamczer D; Alberdi JC; Martínez E; Cosin J; Claramonte X; Gonzalez J; Domingo P; Casado JL; Ribera E;
    N Engl J Med; 2001 Jan; 344(3):159-67. PubMed ID: 11172138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. Swiss HIV Cohort Study.
    Furrer H; Egger M; Opravil M; Bernasconi E; Hirschel B; Battegay M; Telenti A; Vernazza PL; Rickenbach M; Flepp M; Malinverni R
    N Engl J Med; 1999 Apr; 340(17):1301-6. PubMed ID: 10219064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of trimethoprim-sulfamethoxazole, dapsone, and pentamidine in the prophylaxis of Pneumocystis carinii pneumonia.
    Warnock AC; Rimland D
    Pharmacotherapy; 1996; 16(6):1030-8. PubMed ID: 8947975
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis.
    Nachman S; Gona P; Dankner W; Weinberg A; Yogev R; Gershon A; Rathore M; Read JS; Huang S; Elgie C; Hudgens K; Hughes W
    Pediatrics; 2005 Apr; 115(4):e488-94. PubMed ID: 15772172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of the effectiveness of three regimens in the prevention of Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients.
    Martin MA; Cox PH; Beck K; Styer CM; Beall GN
    Arch Intern Med; 1992 Mar; 152(3):523-8. PubMed ID: 1546914
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. Multicenter AIDS Cohort Study.
    Hoover DR; Saah AJ; Bacellar H; Phair J; Detels R; Anderson R; Kaslow RA
    N Engl J Med; 1993 Dec; 329(26):1922-6. PubMed ID: 7902536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: the changes in opportunistic prophylaxis study.
    Mussini C; Pezzotti P; Govoni A; Borghi V; Antinori A; d'Arminio Monforte A; De Luca A; Mongiardo N; Cerri MC; Chiodo F; Concia E; Bonazzi L; Moroni M; Ortona L; Esposito R; Cossarizza A; De Rienzo B
    J Infect Dis; 2000 May; 181(5):1635-42. PubMed ID: 10823763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of atovaquone and azithromycin with trimethoprim-sulfamethoxazole for the prevention of serious bacterial infections in children with HIV infection.
    Hughes WT; Dankner WM; Yogev R; Huang S; Paul ME; Flores MA; Kline MW; Wei LJ;
    Clin Infect Dis; 2005 Jan; 40(1):136-45. PubMed ID: 15614703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose intermittent trimethoprim-sulfamethoxazole for prevention of Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection.
    Wormser GP; Horowitz HW; Duncanson FP; Forseter G; Javaly K; Alampur SK; Gilroy SA; Lenox T; Rappaport A; Nadelman RB
    Arch Intern Med; 1991 Apr; 151(4):688-92. PubMed ID: 1901482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A controlled trial of intravenous immune globulin for the prevention of serious bacterial infections in children receiving zidovudine for advanced human immunodeficiency virus infection. Pediatric AIDS Clinical Trials Group.
    Spector SA; Gelber RD; McGrath N; Wara D; Barzilai A; Abrams E; Bryson YJ; Dankner WM; Livingston RA; Connor EM
    N Engl J Med; 1994 Nov; 331(18):1181-7. PubMed ID: 7935655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interruption of prophylaxis for major opportunistic infections in HIV-infected patients receiving triple combination antiretroviral therapy.
    Jubault V; Pacanowski J; Rabian C; Viard JP
    Ann Med Interne (Paris); 2000 May; 151(3):163-8. PubMed ID: 10896967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neonatal predictors of infection status and early death among 332 infants at risk of HIV-1 infection monitored prospectively from birth. New York City Perinatal HIV Transmission Collaborative Study Group.
    Abrams EJ; Matheson PB; Thomas PA; Thea DM; Krasinski K; Lambert G; Shaffer N; Bamji M; Hutson D; Grimm K
    Pediatrics; 1995 Sep; 96(3 Pt 1):451-8. PubMed ID: 7651777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.